Novel Approach Developed to Better Understand Immune System Defense Mechanism

GEN | November 27, 2019

Scientists from VIB-UGent Center for Medical Biotechnology, the University of Iowa, and other collaborators, say they have developed a new approach to better understand a basic defense mechanism of our immune systems. Central is ISG15, a small protein. To keep control of expressed proteins, cells can attach a chemical “tag” onto a protein to modify its activity. One of the most well-known protein modifications is a small protein called ubiquitin. First discovered as a label to tag a protein for degradation, ubiquitin is now known to have various functions. The labs of Francis Impens, PhD, expert technologist at the VIB-UGent Center for Medical Biotechnology and Lilliana Radoshevich, PhD, assistant professor of microbiology and immunology at the University of Iowa, investigated an ubiquitin-like modification called ISG15. Like ubiquitin, ISG15 can be attached to target proteins. However, the molecular function of ISG15 is elusive, since the identity of the modified proteins and their exact sites of modification are still unknown.

Spotlight

A research team has found that electronic cigarettes, often targeted to youth and pregnant women, produce a stress response in neural stem cells, which are critical cells in the brain.

Spotlight

A research team has found that electronic cigarettes, often targeted to youth and pregnant women, produce a stress response in neural stem cells, which are critical cells in the brain.

Related News

MEDICAL

CosmosID® Enters Microbiome Partnership with Locus Biosciences

CosmosID | June 22, 2022

CosmosID®, an American provider of end-to-end microbiome platforms and award-winning metagenomics services, announced entering into a microbiome partnership with a clinical-stage biotechnology company developing a new class of precision-engineered bacteriophage treatments, Locus Biosciences, Inc. With this partnership, CosmosID focuses on providing its GCP-compliant and CLIA-certified laboratory services for Locus' clinical trial initiatives in the microbiome field. Locus is developing two innovative biotherapeutics categories to meet significant unaddressed medical needs. First, engineered bacteriophage therapies that use bacteria resident in specific body locations to dispatch therapeutic molecules. Second, precision CRISPR-enhanced bacteriophage (crPhage®) products to combat fatal infections, including the ones caused by multi-drug resistant bacteria. Locus is able to swiftly recognize, distinguish, engineer, and produce bacteriophage products against bacterial targets involved in the pathogenesis of numerous diseases by collaborating discovery automation, industry-leading informatics, synthetic biology, and sophisticated in-house manufacturing. CosmosID's infrastructure for providing access to compliant, higher resolution, and robust microbiome analysis will allow Locus to enhance its capability and add insight into precision therapeutics platforms. With its shotgun metagenomics, the company will assist Locus in understanding its products' effectiveness through CosmosID's robust resolution microbiome analysis, commencing with its urinary tract infection clinical program. We're thrilled to partner with Locus on its groundbreaking clinical pipeline as we help the company better understand the impact of these phages on the microbiome, Locus' robust and diligent approach to this study is much needed in the field and we look forward to helping them build a strong clinical data package." Manoj Dadlani, CEO of CosmosID. This partnership with CosmosID will allow Locus to monitor microbiome changes upon treatment of patients with antibiotics and with crPhage, helping us to evaluate the impact of preserving and protecting their microflora while clearing their infections." Paul Garofolo, CEO of Locus Biosciences.

Read More

INDUSTRIAL IMPACT

ProPhase Labs to Announce Formation of a Subsidiary ProPhase BioPharma, Inc.

ProPhase Labs, Inc. | June 29, 2022

ProPhase Labs, Inc., a diversified biotech, genomics, and diagnostics company manufacturing homeopathic and health products, announced the formation of a new wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), for the development and licensing of new therapeutic compounds, drugs, and biotechnology. The subsidiary will be focused on advancements in technology across the biochemical industry and creating and developing new solutions that can transform the outcomes of healthcare. The company has also entered into a license agreement with a wholly-owned subsidiary of DSS, Inc., Global BioLife, Inc. (Global BioLife), for Equivir G and Equivir, proprietary compounds that were developed by Global Research and Discovery Group (GRDG). According to the terms of the contract, ProPhase Labs will be the only company that can develop and sell Equivir G and Equivir, globally. “We are thrilled to announce the formation of ProPhase BioPharma, our new wholly-owned subsidiary tasked with licensing and developing novel drugs, compounds, and biotechnology. We are equally pleased with our first licensing agreement for Equivir and Equivir G, which we believe have significant potential to improve human health outcomes worldwide.” Ted Karkus, ProPhase Lab’s Chief Executive Officer He further added, “We plan to pursue commercialization of Equivir as an OTC supplement, leveraging our distribution in over 40,000 Food Drug and Mass retail stores and online direct to consumer. We also look forward to applying to the FDA for an IND for Equivir G as a prescription antiviral.” Frank. D. Heuszel, Chief Executive Officer of DSS, said “We are excited to team up with ProPhase Labs, which will apply its nearly three decades of experience enhancing the health of the public to Equivir, which we believe to be a ground-breaking treatment that will positively impact health in the U.S. and globally.”

Read More

MEDTECH

Insempra Announces Strategic Investment in Solena Materials

Insempra, | July 26, 2022

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating naturally superior products to drive the regenerative revolution. Solena will be a major part of Insempra’s platform to deliver high-performance, intrinsically sustainable ingredients for a broad array of industries. Solena is using computational design to develop new classes of synthetic proteins to produce high-performance clothing fibers, which can absorb large amounts of kinetic energy. Insempra will accelerate the development and production of these synthetic proteins on an industrial scale, offering better, biobased solutions to the petrochemically sourced, non-biodegradable materials or fibers extracted from nature or animals, such as silk, currently used in the textile and clothing industries. This technology also reduces other environmental impacts such as the rise of microplastics in water bodies coming from washing petrochemically-sourced textiles. “We are hugely excited by this investment in Solena, which will help to accelerate our market-first approach to develop superior, intrinsically sustainable ingredients. We look forward to fast-tracking Solena’s development and production of their unique synthetic proteins to develop customized, high-performance fibers for a variety of applications.” Jens Klein, founder and CEO of Insempra and CEO of Solena Materials Dr James MacDonald, inventor, co-founder and CTO of Solena Materials, added: “The team and I are very excited to make this technology a huge success.” Professor Paul Freemont of Imperial College London, added: “This investment from Insempra recognizes the potential of our technology to revolutionize high-performance fabrics, and their supply chains. Together, we can harness our synthetic biology capabilities to develop, produce and manufacture a new class of superior, more sustainable fiber technology.” Insempra, a co-founder of Solena, will be the sole contributing shareholder in Solena, which is based at Imperial College’s Translation & Innovation Hub (I-HUB) in White City, London. Solena’s Board will be comprised of Dr James MacDonald of Solena, Professor Paul Freemont and Professor Milo Shaffer of Imperial College London, and Jens Klein and Andreas Heyl of Insempra. About Insempra Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products. For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature. Led by a hand-picked team of biologists, technologists and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future. About Solena Materials Solena is a protein materials design company. We use world-leading computational design, machine learning, and automation to accelerate the development of bespoke materials targeted at multiple sectors, from fashion apparel to medical textiles. Our new protein-based fibers will replace materials extracted from nature such as silk and petrochemically-derived materials, to create a new world of biodegradable, functional and sustainable smart materials for consumers, industry, and the planet.

Read More